

From: Ward-Peralta, Cherie
Sent: Friday, November 20, 2015 11:03 AM
To: Fernandez, Alexander Maximilian
Subject: Re: STN 125577 - Information Request - Please respond by
November
25, 2015 (Request for Clarification)

Dear Dr. Fernandez,

We agree with the following proposed language submitted in your email below:

The primary efficacy assessment excludes GI bleeds (n=6 in four subjects), and subjects in whom the number of infusions to control a bleeding episode was estimated retrospectively (n=2).

If you have any additional questions, please contact me.

Thanks
Cherie

From: Fernandez, Alexander Maximilian
Sent: Thursday, November 19, 2015 3:04 PM
To: Ward-Peralta, Cherie
Subject: RE: STN 125577 - Information Request - Please respond by
November 25, 2015 (Request for
Clarification)

Dear Ms. Ward Peralta:

Baxalta would like to get clarification on the following proposed revision (highlighted in yellow) in Section 14 Clinical Studies:
The primary efficacy assessment excludes GI bleeds (n=2), and subjects in whom the number of infusions to control a bleeding episode was estimated retrospectively (n=2).

We don't understand how n=2 was derived. Could you please ask the clinical reviewer to share with us how this number was obtained?

For reference, here is our proposed statement, together with the rationale that was provided on Sep 28, as well as additional notes:
The primary efficacy assessment excludes GI bleeds (n=6 in four subjects), and subjects in whom the number of infusions to control a bleeding episode was estimated retrospectively (n=2).

Rationale:

The number of gastrointestinal bleeds (N=6) is shown in Table 42 (page 132) of the Clinical

Study Report for Study 071001.

The number of subjects with GI bleeds can be derived from pages 123-125 of the Clinical Study Report for Study 071001.

Additional notes:

Phase 3 071001: 6 treated GI bleeds in 4 different subjects:

- Subject (b) (6) BE#3 (severe/major), 1 INF
- Subject (b) (6) BE#2 and BE#8 (both moderate NF per BE
- Subject (b) (6) BE#1 (1 INF) , BE#2 (2 INF)
- Subject (b) (6) BE#2 (severe/major), 2 INF

Many thanks,
Max

Max Fernandez, Ph.D.
Sr. Manager, Global Regulatory Affairs
Baxalta Inc.
One Baxter Way
Westlake Village, CA, 91362 USA
+1 805 372 3048 (TL870) desk
+1 805 372 3082 fax
max.fernandez@baxalta.com
baxalta.com

From: Ward-Peralta, Cherie [mailto:Cherie.Ward-Peralta@fda.hhs.gov]
Sent: Wednesday, November 18, 2015 5:54 AM
To: Fernandez, Alexander Maximilian
Subject: STN 125577 - Information Request - Please respond by November 25, 2015

Our Reference: BL 125577/0

Baxalta US Inc.
Attention: Maximilian Fernandez, PhD
Sent by email

Dear Dr. Fernandez:

We are reviewing your December 19, 2014, biologics license application (BLA) for von Willebrand Factor (Recombinant). We determined that the following information is necessary to continue our review:

Labeling

1. Please revise your package insert according to the tracked changes and comments made within the attached document. We have incorporated changes to replace ADVATE with recombinant Factor VIII except for the description of the clinical trial. The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your response to this information request as an amendment to this file by November 25, 2015 referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

The action due date for this file is December 19, 2015.

Very Respectfully,

Cherie Ward-Peralta, M.S.
Regulatory Project Manager
Office of Blood Research and Review
Center for Biologics Evaluation and Research
10903 New Hampshire Ave
WO-71- 7328
Silver Spring, MD 20993
Phone: 240-402-8447
Email: cherie.ward-peralta@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."